BR9910458A - Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor - Google Patents

Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor

Info

Publication number
BR9910458A
BR9910458A BR9910458-0A BR9910458A BR9910458A BR 9910458 A BR9910458 A BR 9910458A BR 9910458 A BR9910458 A BR 9910458A BR 9910458 A BR9910458 A BR 9910458A
Authority
BR
Brazil
Prior art keywords
enzyme activity
tnf
necrosis factor
tumor necrosis
factors affecting
Prior art date
Application number
BR9910458-0A
Other languages
English (en)
Inventor
Tetsuya Gatanaga
Gale A Granger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9910458A publication Critical patent/BR9910458A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Abstract

Patente de Invenção: <B>''FATORES AFETANDO A ATIVIDADE DE ENZIMA DE LIBERAçãO DE RECEPTOR DE FATOR DE NECROSE DE TUMOR''<D> Os efeitos biológicos da TNF de citocina são mediados por ligação aos receptores sobre a superfície de células. Esta descoberta descreve novas proteínas e polinucleótidos que promovem a divisão enzimática e liberação de receptores de TNF. Também providos são os métodos para identificação de compostos adicionais que influenciam a mudança de receptor de TNF. Como o ingrediente ativo em uma composição farmacêutica, os produtos desta invenção aumentam ou diminuem a transdução de sinal de TNF, desse modo aliviando a patologia de doença.
BR9910458-0A 1998-05-14 1999-05-14 Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor BR9910458A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/081,385 US6593456B1 (en) 1996-11-06 1998-05-14 Tumor necrosis factor receptor releasing enzyme
PCT/US1999/010793 WO1999058559A2 (en) 1998-05-14 1999-05-14 Factors affecting tumor necrosis factor receptor releasing enzyme activity

Publications (1)

Publication Number Publication Date
BR9910458A true BR9910458A (pt) 2001-01-02

Family

ID=22163810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910458-0A BR9910458A (pt) 1998-05-14 1999-05-14 Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor

Country Status (19)

Country Link
US (6) US6593456B1 (pt)
EP (1) EP1076710B1 (pt)
JP (1) JP2002514402A (pt)
KR (1) KR100891899B1 (pt)
CN (1) CN100368547C (pt)
AR (1) AR020588A1 (pt)
AT (1) ATE376063T1 (pt)
AU (1) AU768093B2 (pt)
BR (1) BR9910458A (pt)
CA (1) CA2328133C (pt)
DE (1) DE69937344T2 (pt)
ES (1) ES2294841T3 (pt)
IL (1) IL139566A0 (pt)
MY (1) MY135968A (pt)
NZ (1) NZ507977A (pt)
RU (1) RU2279478C2 (pt)
TW (1) TWI244501B (pt)
WO (1) WO1999058559A2 (pt)
ZA (1) ZA200006475B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
ATE403714T1 (de) 1996-11-06 2008-08-15 Univ California Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
AU2001245371A1 (en) 2000-02-28 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
JP4265402B2 (ja) * 2001-09-25 2009-05-20 ソニー株式会社 ｐ３００ヒストンアセチル化酵素インヒビターを含む転写阻害用組成物及び該ｐ３００ヒストンアセチル化酵素インヒビターを阻害し得る阻害物質のスクリーニング方法
KR101083852B1 (ko) 2002-07-25 2011-11-15 소니 주식회사 유전자 전사 조절제 및 히스톤 탈아세틸화효소 저해 화합물의 스크리닝 방법
US20090204076A1 (en) * 2003-02-03 2009-08-13 Barry Peter Liversidge Medical Injector
CN100375750C (zh) * 2003-05-15 2008-03-19 中国疾病预防控制中心病毒病预防控制所 抑制人肿瘤坏死因子活性的寡聚核苷酸
US7738952B2 (en) * 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
WO2005030241A2 (en) * 2003-09-23 2005-04-07 Meyer Pharmaceuticals, Llc Treating inflammation using a biological agent that causes cells to release cytokine receptors
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
ITRM20050064A1 (it) * 2005-02-16 2006-08-17 Univ Siena Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
TWI527603B (zh) 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
WO2008156676A1 (en) * 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
TWI583418B (zh) 2009-04-29 2017-05-21 艾伯維生物技術有限責任公司 針筒柱塞及自動注射裝置
EP2438046A4 (en) 2009-06-01 2013-04-17 Harvard College O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
TWI619521B (zh) 2009-12-15 2018-04-01 艾伯維生物技術有限責任公司 自動注射裝置、自動注射方法及防止不發射情況之方法
PE20141436A1 (es) 2011-01-24 2014-11-15 Abbvie Biotechnology Ltd Dispositivos de inyeccion automatica con superficies de agarre sobremoldeadas

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) * 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5643740A (en) * 1983-02-24 1997-07-01 Ronald J. Billing Monoclonal antibody specific for activated lymphocytes and monocytes
US5001061A (en) * 1983-06-22 1991-03-19 Lubrizol Genetics, Inc. nifD promoter of Bradyrhizobium
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
JPH0611709B2 (ja) * 1984-10-19 1994-02-16 チロン コーポレイション 角膜基質創傷の治療のための組成物
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
EP0534907B1 (en) * 1991-09-26 1998-08-05 Nippon Zoki Pharmaceutical Co., Ltd. The use of furanone derivatives for the prevention or treatment of autoimmune diseases
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
EP0679716A4 (en) * 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
JP3758187B2 (ja) * 1994-01-28 2006-03-22 味の素株式会社 マガキ由来のトランスグルタミナーゼ
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
ZA955430B (en) 1994-07-07 1997-02-13 Res Dev Foundation Tumor necrosis factor receptor-ii associated protein kinase and method for their use
FR2725213B1 (fr) 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
EP1961760A3 (en) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6090605A (en) * 1996-03-11 2000-07-18 The Board Of Trustees Of The University Of Arkansas Purified porcine kidney L-fucose kinase
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5834236A (en) * 1996-06-27 1998-11-10 The Salk Institute For Biological Studies AATT repeat transcription enhancer element
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
ATE403714T1 (de) * 1996-11-06 2008-08-15 Univ California Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
US6030785A (en) * 1997-03-05 2000-02-29 University Of Washington Screening methods to identify agents that selectively inhibit hepatitis C virus replication
US6911314B2 (en) * 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme

Also Published As

Publication number Publication date
CA2328133C (en) 2009-08-11
ES2294841T3 (es) 2008-04-01
IL139566A0 (en) 2002-02-10
US7399465B2 (en) 2008-07-15
US8101174B2 (en) 2012-01-24
AR020588A1 (es) 2002-05-22
KR20010043586A (ko) 2001-05-25
DE69937344D1 (de) 2007-11-29
US20080102075A1 (en) 2008-05-01
EP1076710B1 (en) 2007-10-17
AU3996099A (en) 1999-11-29
AU768093B2 (en) 2003-12-04
US6955894B1 (en) 2005-10-18
CN100368547C (zh) 2008-02-13
WO1999058559A3 (en) 2000-01-20
ZA200006475B (en) 2001-05-25
CN1309709A (zh) 2001-08-22
WO1999058559B1 (en) 2000-03-16
RU2279478C2 (ru) 2006-07-10
US6593456B1 (en) 2003-07-15
MY135968A (en) 2008-07-31
EP1076710A2 (en) 2001-02-21
US20080160002A1 (en) 2008-07-03
US20050158826A1 (en) 2005-07-21
NZ507977A (en) 2004-04-30
JP2002514402A (ja) 2002-05-21
DE69937344T2 (de) 2008-07-17
TWI244501B (en) 2005-12-01
ATE376063T1 (de) 2007-11-15
CA2328133A1 (en) 1999-11-18
US20050090647A1 (en) 2005-04-28
WO1999058559A2 (en) 1999-11-18
KR100891899B1 (ko) 2009-04-07

Similar Documents

Publication Publication Date Title
BR9910458A (pt) Fatores afetando a atividade de enzima de liberação de receptor de fator de necrose de tumor
Gharibi et al. Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes
Gouze et al. Glucosamine modulates IL‐1‐induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF‐κB pathway
Novack Role of NF-κB in the skeleton
GB2353527A (en) Adenosine A 3 receptor modulators
He et al. Adenosine A 1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling
WO2003014294A3 (en) Tacis and br3 polypeptides and uses thereof
Nakamura et al. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex
BR9911786A (pt) Inibidores heterocìclicos de p38
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
BR9912406A (pt) Compostos de anilida substituida e métodos
DE69928100D1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
Fitzner et al. Galectin-1 is an inductor of pancreatic stellate cell activation
Janelle-Montcalm et al. Extracellular localization of galectin-3 has a deleterious role in joint tissues
BR9811465A (pt) N-triazolil-2-indolcarboxamidas e sua utilização como agonistas de cck-a.
Majewska et al. Role of Tyrosine Kinase Enzymes in TNF‐α and IL‐1 Induced Expression of ICAM‐1 and VCAM‐1 on Human Umbilical Vein Endothelial Cells
Tian et al. Toll-like receptor 2 antagonist ameliorates type 2 diabetes mellitus associated neuropathic pain by repolarizing pro-inflammatory macrophages
BR0207881A (pt) Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropina
Fujita et al. Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
Lan et al. Targeted activation of androgen receptor signaling in the periosteum improves bone fracture repair
Falconi et al. LIF inhibits osteoblast differentiation at least in part by regulation of HAS2 and its product hyaluronan
Khatib et al. Endothelin 1 receptors, signal transduction and effects on DNA and proteoglycan synthesis in rat articular chondrocytes
Chiu et al. Ultrasound stimulates MMP‐13 expression through p38 and JNK pathway in osteoblasts

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements